报 告 内 容 简 介 |
报告人简介：Dr. Nonthaneth Nalinratana is currently a lecturer at the Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University. Specializing in molecular and cellular biology, his focus areas include immuno-oncology, molecular targeted therapy, and cancer research. Dr. Nalinratana's research activities involve drug discovery and development from natural products, novel modalities, and the validation of new drug targets. He has published several research articles and holds international patents, contributing significantly to the field of pharmacological sciences and drug discovery. 报告内容简介： Inflammation plays a crucial role in cancer initiation, progression, and metastasis by creating a tumor-supportive microenvironment. Chronic inflammatory signaling drives genetic and epigenetic alterations that enhance tumor cell proliferation, survival, and metastatic potential. Targeting these pathways presents a promising strategy for cancer prevention and treatment. Natural products have emerged as a valuable source of bioactive compounds with both anti-inflammatory and anti-cancer properties. Among them, phenanthrenes, AI-screened small molecules, and ar-turmerone derivatives have demonstrated potential in modulating key targets such as C-X-C chemokine receptor type 4 (CXCR-4) and cyclooxygenase-2 (COX-2), which are central to inflammation-driven tumor progression and metastasis. Phenanthrene compounds, derived from medicinal plants, have shown potent CXCR4 inhibitory activity, effectively disrupting cancer cell migration and invasion by blocking CXCR4-CXCL12 axis signaling. Beyond natural compounds, AI-driven computational screening has further accelerated the discovery of novel CXCR4-targeting small molecules. Additionally, ar-turmerone derivatives from turmeric exhibit promising COX-2 inhibitory effects, reducing COX-2-mediated inflammatory signaling and suppressing colorectal cancer cell proliferation. This presentation highlights the mechanistic links between inflammation and cancer metastasis while emphasizing the therapeutic potential of natural compounds in targeting these processes. We explore recent advances in drug discovery, including AI-assisted identification of CXCR4 inhibitors, phenanthrene-based small molecules, and ar-turmerone derivatives as COX-2 modulators. By integrating pharmacological, molecular, and computational approaches, this research aims to advance the development of natural product-based therapeutics for inflammation-driven cancer progression. |
